StockData
Latigo Biotherapeutics, Inc. logo

Latigo Biotherapeutics, Inc. (LTGO) stock

LTGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026
$13.31−0.45 (-3.27%)

Close on Nov 18, 2026Market cap $882.44MP/E –Yield 0.00%

Latigo Biotherapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$22.93M–
Q2 FY2026Jun 30, 2026-$25.81M–
Q3 FY2025Sep 30, 2025-$24.72M–
Q2 FY2025Jun 30, 2025-$25.75M–

More Latigo Biotherapeutics figures

See a number that looks wrong?